Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BE Study in Patients - Methotrexate Tablets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02940561
Recruitment Status : Unknown
Verified October 2016 by Amneal Pharmaceuticals, LLC.
Recruitment status was:  Recruiting
First Posted : October 21, 2016
Last Update Posted : October 21, 2016
Sponsor:
Collaborator:
Accutest Research Laboratories (I) Pvt. Ltd.
Information provided by (Responsible Party):
Amneal Pharmaceuticals, LLC

Brief Summary:
To characterize the pharmacokinetic profile of the Test product - Methotrexate Tablets USP, 2.5 mg of Amneal Pharmaceuticals, compared to that of the corresponding Reference product - Methotrexate Tablets USP 2.5 mg manufactured for DAVA Pharmaceuticals, Inc. in patients with mild to severe psoriasis or rheumatoid arthritis, who are already on established regimens of 2.5 mg every 12 hours for three doses per week under fasting conditions, and to assess their bioequivalence.

Condition or disease Intervention/treatment Phase
Psoriasis Rheumatoid Arthritis Drug: Methotrexate - Amneal Drug: Methotrexate - DAVA Phase 1

Detailed Description:

Patients will continue their own established dose of 2.5 mg tablet at 12 hours intervals for 3 doses given as a course once weekly. This dosing regimen will be kept constant throughout the study period.

On day 0 of each period, the patient will be hospitalized/ housed in the clinical facility/hospital, so patient will be administered IP dose on day 1 under supervision of trained study staff.

In supervised dosing, patient will be administered oral dose of Methotrexate Tablet 2.5 mg (Test or Reference product as per randomization schedule) with approximately 240 mL of water at ambient temperature in sitting position. Mouth check will be done by investigator/ designee followed by IP administration to verify dosing compliance.

The patient will be advised to take two subsequent doses of the locally approved drug at every 12 hours of interval after the administration of study drug on day 1.

Compliance to subsequent two doses of locally approved Methotrexate tablets 2.5 mg will be ensured as below in each period.

The dose which is to be given 12 hours after IP administration (Second dose) will be administered inside clinical facility after collection of 12 hours post-dose PK sample under supervision of trained study personnel. The next dose (third dose) will be provided to the patients with the instruction to take the same on their own. Telephonic follow-up will be made on the next day for this third dose. The same will be documented in the patient dosing log.

In period I, patient will be housed on day 0 at least 12 hours prior to IP dosing scheduled on day 1 and will remain in clinical facility till last PK sample on day 1. Patient will be checked out on day 1 after last PK blood sample collection followed by administration of second dose of locally approved Methotrexate 2.5 mg tablet. The third dose of locally approved Methotrexate 2.5 mg tablet should be taken by patient on their own approximately 12 hours after the second dose.

The same procedure will be followed in period II.

There will be a period of at least 7 days between first dosing (IP administration) in both the study periods.

The patients will have to stay hospitalized for a period of 2 days and 1 night in each study period for their convenience and close safety monitoring.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Multicenter, Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single-dose, Two-way, Crossover, Bioequivalence Study of Methotrexate Tablets USP, 2.5 mg Manufactured by Amneal Pharmaceuticals, With Methotrexate Tablets USP 2.5 mg Manufactured for DAVA Pharmaceuticals, Inc., Fort Lee, NJ 07024 USA in Patients With Mild to Severe Psoriasis or Rheumatoid Arthritis, Who Are Already on Established Regimens of 2.5 mg Every 12 Hours Under Fasting Condition.
Study Start Date : August 2016
Estimated Primary Completion Date : October 2016
Estimated Study Completion Date : October 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Methotrexate - Amneal
Methotrexate Tablets USP, 2.5 mg, single-dose in each period
Drug: Methotrexate - Amneal
Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with "A" above the score and "1" below
Other Name: Methotrexate Sodium

Active Comparator: Methotrexate - DAVA
Methotrexate Tablets USP, 2.5 mg, single-dose in each period
Drug: Methotrexate - DAVA
Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
Other Name: Methotrexate Sodium




Primary Outcome Measures :
  1. Area Under the Curve (AUC0-12) [ Time Frame: Blood samples will be collected on day 1 of each period, pre-dose and post-dose at 0.167, 0.333, 0.500, 0.750, 1.000, 1.250, 1.500, 1.750, 2.000, 2.333, 2.667, 3.000, 3.500, and 4 hours ]
    The area under the plasma concentration versus time curve, from time 0 to 12 hours post-dose, calculated using linear trapezoidal method. It will be calculated using plasma concentration vs. time profile (Actual time of sample collection) data of the investigational products in individual subjects.

  2. Maximum Plasma Concentration (Cmax) [ Time Frame: Blood samples will be collected on day 1 of each period, pre-dose and post-dose at 0.167, 0.333, 0.500, 0.750, 1.000, 1.250, 1.500, 1.750, 2.000, 2.333, 2.667, 3.000, 3.500 and 4 hours ]
    Maximum measured plasma concentration over the time span specified. It will be calculated using plasma concentration vs. time profile (Actual time of sample collection) data of the investigational products in individual subjects.


Secondary Outcome Measures :
  1. Safety Parameters [ Time Frame: through study completion, approximately 23 days ]
    Safety parameters will include monitoring of AEs, SAEs, physical examination results, vital signs and clinical laboratory results



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with mild to severe psoriasis or rheumatoid arthritis, who are already on established regimens of 2.5 mg every 12 hours (7.5 mg per week in three divided doses)
  • Confirmed diagnosis of psoriasis by clinical examination or after dermatologic consultation.

or confirmed diagnosis of mild to severe rheumatoidarthritis based on at least 1 of the following: i. Documented history of positive rheumatoid factor ii. Current presence of rheumatoid factor iii. Radiographic erosion within 12 months prior to enrollment iv. Presence of serum anti-cyclic citrullinated peptide antibodies (anti-CCP).

  • Women of childbearing potential (include girls who have entered puberty and all women who have a uterus and ovaries and have not completed menopause wherein menopause is the permanent end of menstruation and fertility. Females who have 12 consecutive months of spontaneous amenorrhea (not induced by a medical condition or medical therapy) or have bilateral absence of ovaries (surgical or congenital) have completed menopause must have a negative serum pregnancy test at screening and negative urine pregnancy test on check in to housing, and must agree to use an adequate method of contraception.
  • Patient's screening laboratory assessment (complete blood count [CBC] and blood chemistries) are clinically non-significant as per the discretion of the Investigator.
  • No history of addiction to any recreational drug or drug dependence.
  • No participation in any clinical study within the past 60 days prior to receiving the first dose of investigational product for the current study.

Exclusion Criteria:

  • A history of allergic or adverse reactions to Methotrexate Sodium or any related drug or any excipient of methotrexate tablets.
  • Females of childbearing potential unwilling to use adequate contraception (as defined in the protocol) throughout the trial and for one month after the last dose of study medication.
  • Males unwilling to use a male condom throughout the trial and for three months after the last dose of study medication
  • Patients with alcoholism, alcoholic liver disease or other chronic liver disease.
  • Patients who are diagnosed to be HIV or Hepatitis B (HBsAg) or Hepatitis C (HCV) virus reactive/positive.
  • Patients who have clinically significant abnormal laboratory values at screening.
  • Patients with any evidence of organ dysfunction or any clinically significant deviation from normal in their physical or clinical evaluation including ECG and X-ray results except study indication.
  • Patients who have overt or laboratory evidence of immunodeficiency syndromes.
  • Patients currently suffering from or having a history of malignant lymphoma or tumor lysis syndrome.
  • Patients who have pre-existing hematopoietic impairment/ blood dyscrasias, such as bone marrow hypoplasia, aplastic anemia, pancytopenia, leukopenia, neutropenia, thrombocytopenia and or significant anemia.
  • Patient with lymphadenopathy and lymphoproliferative disorders.
  • Patients suffering from any acute infection within two weeks prior to randomization.
  • Patients with a clinically significant past history or current medical condition of: Pulmonary disorders (Pneumonia, COPD and asthma), pleural effusions, Cardiovascular disorders (especially cardiac blocks, pericarditis, pericardial effusion, hypotension and thromboembolic events ), Neurological disorders (especially seizures, migraines), Gastrointestinal tract disorders including a history or presence of significant gastric and/or duodenal ulceration and bleeding, hematemesis, melena, enteritis, pancreatitis, Renal and/or hepatic disorders, Coagulation disorders, Patient with ascites, Patient with uncontrolled diabetes mellitus.
  • Female patients who are pregnant or breastfeeding
  • History or presence of cancer.
  • Evidence of any significant uncontrolled concomitant disease which in the investigator's opinion would exclude the patient participation.
  • Expected changes in concomitant medications during the period of study.
  • Tested positive for Alcohol breath or Urine drug of abuse.
  • Any treatment which could affect the pharmacokinetic of methotrexate (NSAIDs, salicylates, hypoglycemics, diuretics, sulphonamides, diphenylhydantoins, tetracyclines, chloramphenicol and p-aminobenzoic acid, probenecid, penicillins, Chloroquine, omeprazole, etretinate, co-trimoxazole and trimethoprim etc.) administered within 1 month of starting of study.
  • Patient had major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery.
  • Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • Patients for whom oral administration of drug is not possible.
  • An unusual or abnormal diet, for whatever reason e.g. religious fasting.
  • Blood donation/ loss exceeding 200 ml within last 60 days prior to receiving the first dose of investigational product for the current study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02940561


Contacts
Layout table for location contacts
Contact: Prayag N Shah, MD +91 8128671400 Dr.Prayag@amneal.com

Locations
Layout table for location information
India
Saviour Hospital Recruiting
Ahmedabad, Gujarat, India, 380009
Contact: Smita Nagpal, MD    9825721525    nagpalsmita@gmail.com   
Principal Investigator: Smita Nagpal, MD         
Sub-Investigator: Khushbu Jain, MD         
Sub-Investigator: Ravindra Wadhawan, MD         
Sterling Hospital Recruiting
Ahmedabad, Gujarat, India, 380052
Contact: Piyush Joshi, MD    +91 8879102056    pnjoshi2005@gmail.com   
Principal Investigator: Piyush Joshi, MD         
Sub-Investigator: Sapan C Pandya, MD         
Kanoria Hospital Recruiting
Gandhinagar, Gujurat, India, 382428
Contact: Saurabh Kapadia, MD    +91-9824261031    drsaurabhkapadia@yahoo.com   
Principal Investigator: Saurabh Kapadia, MD         
Sponsors and Collaborators
Amneal Pharmaceuticals, LLC
Accutest Research Laboratories (I) Pvt. Ltd.
Investigators
Layout table for investigator information
Study Director: Prayag N Shah, MD Amneal Pharmaceuticals
Layout table for additonal information
Responsible Party: Amneal Pharmaceuticals, LLC
ClinicalTrials.gov Identifier: NCT02940561    
Other Study ID Numbers: 15-VIN-515
First Posted: October 21, 2016    Key Record Dates
Last Update Posted: October 21, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Psoriasis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors